{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/020/SRR28601920/SRR28601920_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/022/SRR28601922/SRR28601922_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/016/SRR28601916/SRR28601916_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/018/SRR28601918/SRR28601918_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/017/SRR28601917/SRR28601917_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/016/SRR28601916/SRR28601916_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/019/SRR28601919/SRR28601919_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/020/SRR28601920/SRR28601920_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/022/SRR28601922/SRR28601922_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/021/SRR28601921/SRR28601921_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/019/SRR28601919/SRR28601919_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/015/SRR28601915/SRR28601915_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/021/SRR28601921/SRR28601921_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/017/SRR28601917/SRR28601917_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/018/SRR28601918/SRR28601918_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR286/015/SRR28601915/SRR28601915_2.fastq.gz"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Theomics International Private Limited"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA1098067"],"scientific_name":["Drosophila melanogaster"],"long_description":["Supplementation of Urolithin-A, a catabolite of ellagic acid-containing precursors, has been shown to benefit the central nervous system (CNS). This study focused on deciphering the potential anti-epileptic effects of Urolithin-A, a small molecule of natural origin. To understand the primary underlying mediators of UA’s anti-epileptic efficacy, RNA sequencing was performed in the sub-acute epileptic model of Drosophila (4 hours of treatment duration with epileptic inducer-picrotoxin (PTX)) to abstain from the interference of secondary pathways. Four treatment groups were included in the study: 1) Vehicle (0.5% DMSO), 2) 1mM PTX, 3) 1mM PTX + Urolithin-A (100µM), and 4) Urolithin-A (100µM). Administration of Urolithin-A restores the PTX-induced misregulated genes of brain hemolymph and metabolic dysfunctions. Overall design: The picrotoxin-induced sub-acute seizure model of Drosophila was included in the study. The sub-acute name is given according to the short treatment duration of 4 hours. Four treatment groups were included in the study: 1) Vehicle (0.5% DMSO), 2) 1mM PTX, 3) 1mM PTX + Urolithin-A (100µM), and 4) Urolithin-A (100µM). PTX represents the epileptic context."],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Urolithin A mitigates behavioral and synaptic deficits associated with epilepsy through VDAC-1 inhibition: A novel treatment approach","description":"Urolithin A mitigates behavioral and synaptic deficits associated with epilepsy through VDAC-1 inhibition: A novel treatment approach","dates":{"last_updated":"2025-09-24","first_public":"2025-04-12"},"accession":"PRJNA1098067","cross_references":{"GEO":["GSE263560"],"taxon":["7227"]}}